Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Picture life cycle management in pharma?Rexulti pharmaceutical company ketamine evaluation?Ocrevus patent expiry uk?Famotidine api patent expiry date?Sodium nitro prusside?
See the DrugPatentWatch profile for Etomidate
Etomidate (often given as the anesthesia induction drug etomidate) has a short elimination half-life. Reported values are about 2 to 5 hours, depending on the source and patient/clinical context [1].
The measured “half-life” can differ across references because it depends on how it’s estimated (pharmacokinetic model, sampling timing) and on factors like patient metabolism and organ function. Etomidate is typically given as an IV bolus or infusion for anesthesia, so clinicians also rely on rapid clinical onset and offset rather than only the half-life [1].
Even with an elimination half-life on the order of hours, the hypnotic effect during induction often wears off quickly because drug concentrations fall from the brain faster than total body elimination. That’s why patients may recover from anesthesia effects sooner than a half-life would suggest [1].
Half-life can be reported differently for different studies (IV vs infusion protocols). If you tell me the dosing regimen (bolus vs infusion) and the context (adult vs pediatric, normal vs impaired liver/kidney), I can narrow to the most relevant half-life range from the cited source [1].
[1] DrugBank – Etomidate: https://go.drugbank.com/drugs/DB01005
Other Questions About Etomidate :